BOSTON & SHENZHEN, China--(BUSINESS WIRE)--Signet Therapeutics, a clinical-stage biotech company leveraging organoid- and AI-driven cancer drug discovery, announced that the U.S. Food and Drug ...
Hereditary gastric cancer syndromes encompass a group of genetically determined conditions that confer a markedly increased risk of developing gastric malignancies. Central to these syndromes is ...
To sum up, many things can raise the risk of stomach cancer. These include H. pylori infection, diet, smoking, family history ...
Signet Therapeutics Inc. has received IND clearance from the FDA for SIGX-1094 as a potential treatment for diffuse gastric cancer. A phase I trial is planned in patients with diffuse gastric cancer ...
BOSTON--(BUSINESS WIRE)--Signet Therapeutics, a biotech company using organoid disease models and AI to advance targeted cancer therapy, today announced that the FDA has granted its IND application ...
Patients carrying at least one of the four key genes show a significantly increased risk for disease recurrence and mortality in gastric cancer, according to new research that potentially paves the ...
Signet Therapeutics founder Haisheng Zhang is betting on organoids and AI to outsmart diffuse gastric cancer and the limits of traditional “clean” drug design.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results